139 related articles for article (PubMed ID: 15491387)
1. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.
Tanaka H; Suzuki K; Nakahata T; Tsugawa K; Konno Y; Tsuruga K; Ito E; Waga S
Pediatr Int; 2004 Oct; 46(5):576-9. PubMed ID: 15491387
[TBL] [Abstract][Full Text] [Related]
2. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
Renke M; Tylicki L; Rutkowski P; Rutkowski B
Scand J Urol Nephrol; 2004; 38(5):427-33. PubMed ID: 15764256
[TBL] [Abstract][Full Text] [Related]
3. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
Tylicki L; Rutkowski P; Renke M; Rutkowski B
Am J Nephrol; 2002; 22(4):356-62. PubMed ID: 12169868
[TBL] [Abstract][Full Text] [Related]
4. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis.
Woo KT; Lau YK; Wong KS; Chiang GS
Kidney Int; 2000 Dec; 58(6):2485-91. PubMed ID: 11115082
[TBL] [Abstract][Full Text] [Related]
5. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
Russo D; Minutolo R; Pisani A; Esposito R; Signoriello G; Andreucci M; Balletta MM
Am J Kidney Dis; 2001 Jul; 38(1):18-25. PubMed ID: 11431176
[TBL] [Abstract][Full Text] [Related]
6. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.
Horita Y; Tadokoro M; Taura K; Suyama N; Taguchi T; Miyazaki M; Kohno S
Hypertens Res; 2004 Dec; 27(12):963-70. PubMed ID: 15894837
[TBL] [Abstract][Full Text] [Related]
7. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
[TBL] [Abstract][Full Text] [Related]
8. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation.
Ots M; Mackenzie HS; Troy JL; Rennke HG; Brenner BM
J Am Soc Nephrol; 1998 Feb; 9(2):224-30. PubMed ID: 9527398
[TBL] [Abstract][Full Text] [Related]
9. Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy.
Yagi K; Okada M; Yanagida H; Kuwajima H; Ikeda M; Sugimoto K; Takemura T
Clin Exp Nephrol; 2003 Dec; 7(4):270-4. PubMed ID: 14712355
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of multidrug therapy combined with mizoribine in children with diffuse IgA nephropathy in comparison with multidrug therapy without mizoribine and with methylprednisolone pulse therapy.
Kawasaki Y; Hosoya M; Suzuki J; Onishi N; Takahashi A; Isome M; Nozawa R; Suzuki H
Am J Nephrol; 2004; 24(6):576-81. PubMed ID: 15550753
[TBL] [Abstract][Full Text] [Related]
11. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
12. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria.
Ellis D; Vats A; Moritz ML; Reitz S; Grosso MJ; Janosky JE
J Pediatr; 2003 Jul; 143(1):89-97. PubMed ID: 12915830
[TBL] [Abstract][Full Text] [Related]
13. Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis.
Tylicki L; Renke M; Rutkowski P; Rutkowski B; Lysiak-Szydłowska W
Med Sci Monit; 2005 Apr; 11(4):PI31-7. PubMed ID: 15795705
[TBL] [Abstract][Full Text] [Related]
14. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy.
Russo D; Pisani A; Balletta MM; De Nicola L; Savino FA; Andreucci M; Minutolo R
Am J Kidney Dis; 1999 May; 33(5):851-6. PubMed ID: 10213639
[TBL] [Abstract][Full Text] [Related]
15. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
[TBL] [Abstract][Full Text] [Related]
17. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
[TBL] [Abstract][Full Text] [Related]
18. Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes.
Cetinkaya R; Odabas AR; Selcuk Y
Int J Clin Pract; 2004 May; 58(5):432-5. PubMed ID: 15206496
[TBL] [Abstract][Full Text] [Related]
19. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
Agarwal R; Siva S; Dunn SR; Sharma K
Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
[TBL] [Abstract][Full Text] [Related]
20. Progression of renal failure delayed by use of losartan in a case of IgA nephropathy.
Iseki K; Takishita S
Intern Med; 2002 Dec; 41(12):1167-70. PubMed ID: 12521208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
